Drug delivery with a calixpyrrole-trans -Pt(II) complex

Journal of the American Chemical Society

Volumn 135, Issue 7, 2013, Pages 2544-2551

  Cafeo, Grazia ^a   Carbotti, Grazia ^b   Cuzzola, Angela ^c   Fabbi, Marina ^b   Ferrini, Silvano ^b   Kohnke, Franz H ^a   Papanikolaou, Georgia ^a   Plutino, Maria Rosaria ^a   Rosano, Camillo ^b   White, Andrew J P ^d  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE MONOPHOSPHATE; ANION-BINDING; CALIX[4]PYRROLE; CANCER CELL LINES; CYTOTOXIC ACTIVITIES; H-BONDING; IN-VITRO TESTS; MODEL COMPOUND; NUCLEOBASES; PRESENCE OF WATER; PT COMPLEXES; PYRROLE DERIVATIVES;

AROMATIC COMPOUNDS; BINDING ENERGY; CELL CULTURE; DRUG DELIVERY; PLATINUM;

PLATINUM COMPOUNDS;

ADENOSINE PHOSPHATE; ANION; CALIX[4]PYRROLE; CARBOPLATIN; CYTOTOXIC AGENT; NUCLEIC ACID BASE; OXALIPLATIN; PHOSPHATE; PLATINUM; PYRROLE DERIVATIVE; SOLVENT; UNCLASSIFIED DRUG; WATER;

ARTICLE; CANCER CELL CULTURE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DIMERIZATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; NUCLEAR MAGNETIC RESONANCE; X RAY ANALYSIS;

ANTINEOPLASTIC AGENTS; CALIXARENES; CELL LINE, TUMOR; CELL SURVIVAL; COORDINATION COMPLEXES; CRYSTALLOGRAPHY, X-RAY; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLATINUM; PYRROLES;

EID: 84874058421     PISSN: 00027863     EISSN: 15205126     Source Type: Journal    
DOI: 10.1021/ja307791j     Document Type: Article

References (53)

1. Venkataraman, S.; Hedrick, J. L.; Ong, Z. Y.; Yang, C.; Ee, P. L. R.; Hammond, P. T.; Yang, Y. Y. Adv. Drug Delivery Rev. 2011, 63, 1228-1246
2. Yang, K.; Weng, L.; Cheng, Y.; Zhang, H.; Zhang, J.; Wu, Q.; Xu, T. J. Phys. Chem. B 2011, 115, 2185-2195
3. Medina, S. H.; El-Sayed, M. E. H. Chem. Rev. 2009, 109, 3141-3157
4. Tekade, R. K.; Kumar, P. V.; Jain, N. K. Chem. Rev. 2009, 109, 49-87
5. Fang, J.; Nakamura, H.; Maeda, H. Adv. Drug Delivery Rev. 2011, 63, 136-151
6. Bei, D.; Meng, J.; Youan, B.-B. C. Nanomedicine (London, United Kingdom) 2010, 5, 1385-1399
7. Rao, J. ACS Nano 2008, 2, 1984-1986
8. Haag, R.; Kratz, F. Angew. Chem., Int. Ed. 2006, 45, 1198-1215
9. Teow, Y.; Valiyaveettil, S. Nanoscale 2010, 2, 2607-2613
10. Low, P. S.; Henne, W. A.; Doorneweerd, D. D. Acc. Chem. Res. 2008, 41, 120-129
11. van Zutphen, S.; Reedijk, J. Coord. Chem. Rev. 2005, 249, 2845-2853
12. Ndinguri, M. W.; Solipuram, R.; Gambrell, R. P.; Aggarwal, S.; Hammer, R. P. Bioconjugate Chem. 2009, 20, 1869-1878
13. Mukhopadhyay, S.; Barnes, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. Bioconjugate Chem. 2008, 19, 39-49
14. Abu-Surrah, A. S.; Kettunen, M. Curr. Med. Chem. 2006, 13, 1337-1357
15. van Zutphen, S.; Pantoja, E.; Soriano, R.; Soro, C.; Tooke, D. M.; Spek, A. L.; den Dulk, H.; Brouwer, J.; Reedijk, J. Dalton Trans. 2006, 1020-1023
16. Kapp, T.; Dullin, A.; Gust, R. Bioconjugate Chem. 2010, 21, 328-337
17. Chen, G. J.; Kumar, J.; Gregory, A.; Stenzel, M. H. Chem. Commun. 2009, 6291-6293
18. Malik, N.; Evagorou, E. G.; Duncan, R. Anticancer Drugs 1999, 10, 767-776
19. Harper, B. W.; Krause-Heuer, A. M.; Grant, M. P.; Manohar, M.; Garbutcheon-Singh, K. B.; Aldrich-Wright, J. R. Chem.-Eur. J. 2010, 16, 7064-7077
20. Aris, S. M.; Farrell, N. P. Eur. J. Inorg. Chem. 2009, 1293-1302
21. Coluccia, M.; Natile, G. Anti-Cancer Agents Med. Chem. 2007, 7, 111-123
22. Kelland, L. Nat. Rev. Cancer 2007, 7, 573-584
23. Radulovic, S.; Tesic, Z.; Manic, S. Curr. Med. Chem. 2002, 9, 1611-1618
24. Natile, G.; Coluccia, M. Coord. Chem. Rev. 2001, 216-217, 383-410
25. Gale, P. A.; Anzenbacher, P.; Sessler, J. L. Coord. Chem. Rev. 2001, 222, 57-102
26. Gale, P. A.; Sessler, J. L.; Kral, V. Chem. Commun. 1998, 1-8
27. Custelcean, R.; Delmau, L. H.; Moyer, B. A.; Sessler, J. L.; Cho, W.-S.; Gross, D.; Bates, G. W.; Brooks, S. J.; Light, M. E.; Gale, P. A. Angew. Chem., Int. Ed. 2005, 44, 2537-2542
28. Allen, W. E.; Gale, P. A.; Brown, C. T.; Lynch, V. M.; Sessler, J. L. J. Am. Chem. Soc. 1996, 118, 12471-12472
29. Gale, P. A. Acc. Chem. Res. 2011, 44, 216-226
30. Sessler, J. L.; Gale, P. A.; Genge, J. W. Chem.-Eur. J. 1998, 4, 1095-1099
31. Whan, R. M.; Messerle, B. A.; Hambley, T. W. Dalton Trans. 2009, 932-939
32. Osa, T.; Hino, H.; Fujieda, S.; Shimizu, F.; Arakawa, M. Chem. Pharm. Bull. 1986, 34, 1881-1887
33. Yang, W.; Yin, Z.; Wang, C.-H.; Huang, C.; He, J.; Zhu, Xi.; Cheng, J.-P. Tetrahedron 2008, 64, 9244-9252
34. Bruno, G.; Cafeo, G.; Kohnke, F. H.; Nicolo, F. Tetrahedron 2007, 63, 10003-10010
35. Kong, P.-C.; Rochon, F. D. Inorg. Chim. Acta 1982, 61, 269-271
36. Szuecova, L.; Travnicek, Z.; Popa, I.; Marek, J. Polyhedron 2008, 27, 2710-2720
37. Guido, E.; D'Amico, G.; Russo, N.; Sicilia, E.; Rizzato, S.; Albinati, A.; Romeo, A.; Plutino, M. R.; Romeo, R. Inorg. Chem. 2011, 50, 2224-2239 and refs therein
38. Anzenbacher, P., Jr.; Jursikova, K.; Lynch, V. M.; Gale, P. A.; Sessler, J. L. J. Am. Chem. Soc. 1999, 121, 11020-11021
39. Pregosin, P. S. Platinum NMR Spectrosc. Annu. Rep. NMR Spectrosc. 1986, 17, 285-349
40. Lippert, B. In Progress in Inorganic Chemistry; Lippard, S. J., Ed.; Wiley: New York, 1989; Vol. 37, pp 1-97.
41. Monsù Scolaro, L.; Mazzaglia, A.; Romeo, A.; Plutino, M. R.; Castriciano, M.; Romeo, R. Inorg. Chim. Acta 2002, 330, 189-196
42. Cafeo, G.; Lo Passo, C.; Monsù Scolaro, L.; Pernice, I.; Romeo, R. Inorg. Chim. Acta 1998, 275-276, 141-149
43. Cacciapaglia, R.; Di Stefano, S.; Mandolini, L. Acc. Chem. Res. 2004, 37, 113-122
44. The normal concentration of chloride in plasma should be between 8 and 16 mM; from http://www.medicalhealthtests.com/blog/pathology-test/chloride-plasma. html.
45. Dijt, F. J.; Canters, G. W.; den Hartog, J. H. J.; Marcelis, A. T. M.; Reedijk, J. J. Am. Chem. Soc. 1984, 106, 3644-3647
46. Martin, R. B. Acc. Chem. Res. 1985, 18, 32-38
47. Navarro, J. A. R.; Lippert, B. Coord. Chem. Rev. 1999, 185-186, 653-667
48. Buschmann, H.-J.; Schollmeyer, E.; Cleve, E.; Mutihac, L. Anal. Lett. 2011, 44, 2703-2710
49. Yi, Y. W.; Insoo, B. DNA Repair 2011, 10, 1084-1085
50. Fischer, S. J.; Benson, L. M.; Fauq, A.; Naylor, S.; Windebank, A. J. NeuroToxicology 2008, 29, 444-452
51. Eastman, A. The Mechanism of Action of Cisplatin: From Adducts to Apoptosis. In Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed.; Wiley-VCH: Basel, Switzerland, 1999; pp 111-134
52. Pestell, K. E.; Hobbs, S. M.; Titley, J. C.; Kelland, L. R.; Walton, M. I. Mol. Pharmacol. 2000, 57, 503-511
53. Gonzalez, V. M.; Fuertes, M. A.; Alonso, C.; Perez, J. M. Mol. Pharmacol. 2001, 59, 657-663